Home / Latest Reports / Pulmonary Arterial Hypertension Market

Pulmonary Arterial Hypertension Market by Drug Class - Global Industry Analysis & Forecast to 2027

Published On : April 2019 Pages : 168 Category: Pharma & Healthcare Report Code : HC043419

Request Sample Inquiry Before Buying Request for Customization Check Discount

Pulmonary Arterial Hypertension Market by Drug Class (PDE-5, Prostacyclin and Prostacyclin Analogs, SGC Stimulators, ERA) - Global Industry Analysis & Forecast to 2027

Industry Outlook and Trend Analysis

The Pulmonary Arterial Hypertension Market has encountered significant development over the recent years and is anticipated to grow tremendously over the forecast period. Pulmonary arterial hypertension (PAH) is a phenomenal sort of dynamic ailment connected with hypertension. However, the recent couple of years, the expanding pervasiveness of PAH issue because of rising danger factors, for example, HIV, inactive way of life, tobacco and liquor utilization, smoking, and other idiopathic conditions. According to the investigation led by World Health Organization and Center for Disease Control and Prevention proposes that the pervasiveness of PAH is assessed to 15 to 50 cases for each million heads, and there is no everlasting solution for this issue present in the market.

Drivers and Restraints

Different treatments are accessible in the market that helps in controlling and hindering the development of the ailments and improves the personal satisfaction. Likewise, the endorsement of couple of successful medications and the event of ideal pipeline are some of essential factors that drive the market development. Advantageous schemes by government have contributed in boosting the interest in the worldwide aspiratory blood vessel hypertension market.

Regional Insights

North America ruled the worldwide pneumonic blood vessel hypertension advertise and is anticipated to proceed with its predominance by contributing the main share of the market.

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • India
    • Southeast Asia
    • Rest of Asia-Pacific
  • South America
    • Brazil
    • Argentina
    • Columbia
    • Rest of South America
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Egypt
    • Nigeria
    • South Africa
    • Rest of MEA

Competitive Analysis                         

The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.

  • Gilead Sciences, Inc.
  • United Therapeutics Corporation
  • Novartis International AG
  • Actelion Pharmaceuticals, Ltd
  • Dong-A ST Co., Ltd.
  • Pfizer, Inc.
  • Merck Sharp & Dohme Corp.
  • GlaxoSmithKline Plc. (GSK)
  • Arena Pharmaceuticals
  • Bayer HealthCare

Some of the key questions answered by the report are:

  • What was the market size in 2017 and forecast from 2017 to 2027?
  • What will be the industry market growth from 2017 to 2027?
  • What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
  • What are the major segments leading the market growth and why?
  • Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?

Market Classification

·         Pulmonary Arterial Hypertension Market, By Drug Class, Estimates and Forecast, 2017-2027 ($Million)

o    PDE-5

o    Prostacyclin and Prostacyclin Analogs

o    SGC Stimulators

o    ERA

·         Pulmonary Arterial Hypertension Market, By Key Players

o    Gilead Sciences, Inc.

o    United Therapeutics Corporation

o    Novartis International AG

o    Actelion Pharmaceuticals, Ltd

o    Dong-A ST Co., Ltd.

o    Pfizer, Inc.

o    Merck Sharp & Dohme Corp.

o    GlaxoSmithKline Plc. (GSK)

o    Arena Pharmaceuticals

o    Bayer HealthCare

·         Pulmonary Arterial Hypertension Market, By Region, Estimates and Forecast, 2017-2027 ($Million)

o    North America

§  North America Pulmonary Arterial Hypertension Market, By Country

o    U.S. Pulmonary Arterial Hypertension Market

o    Canada Pulmonary Arterial Hypertension Market

o    Mexico Pulmonary Arterial Hypertension Market

o    Europe

§  Europe Pulmonary Arterial Hypertension Market, By Country

o    Germany Pulmonary Arterial Hypertension Market

o    UK Pulmonary Arterial Hypertension Market

o    France Pulmonary Arterial Hypertension Market

o    Russia Pulmonary Arterial Hypertension Market

o    Italy Pulmonary Arterial Hypertension Market

o    Rest of Europe Pulmonary Arterial Hypertension Market

o    Asia-Pacific

§  Asia-Pacific Pulmonary Arterial Hypertension Market, By Country

o    China Pulmonary Arterial Hypertension Market

o    Japan Pulmonary Arterial Hypertension Market

o    South Korea Pulmonary Arterial Hypertension Market

o    India Pulmonary Arterial Hypertension Market

o    Southeast Asia Pulmonary Arterial Hypertension Market

o    Rest of Asia-Pacific Pulmonary Arterial Hypertension Market

o    South America

§  South America Pulmonary Arterial Hypertension Market

o    Brazil Pulmonary Arterial Hypertension Market

o    Argentina Pulmonary Arterial Hypertension Market

o    Columbia Pulmonary Arterial Hypertension Market

o    Rest of South America Pulmonary Arterial Hypertension Market

o    Middle East and Africa

§  Middle East and Africa Pulmonary Arterial Hypertension Market

o    Saudi Arabia Pulmonary Arterial Hypertension Market

o    UAE Pulmonary Arterial Hypertension Market

o    Egypt Pulmonary Arterial Hypertension Market

o    Nigeria Pulmonary Arterial Hypertension Market

o    South Africa Pulmonary Arterial Hypertension Market

o    Rest of MEA Pulmonary Arterial Hypertension Market

Table of Contents:

1.       Introduction

1.1.     Report Description

2.       Executive Summary

2.1.     Key Highlights

3.       Market Overview

3.1.     Introduction

3.1.1.  Market Definition

3.1.2.  Market Segmentation

3.2.     Market Dynamics

3.2.1.  Drivers

3.2.2.  Restraints

3.2.3.  Opportunities

3.3.     SWOT Analysis

4.       Market Analysis by Regions

4.1.     North America (United States, Canada and Mexico)

4.1.1.  United States Market Status and Outlook (2017-2027)

4.1.2.  Canada Market Status and Outlook (2017-2027)

4.1.3.  Mexico Market Status and Outlook (2017-2027)

4.2.     Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

4.2.1.  Germany Market Status and Outlook (2017-2027)

4.2.2.  France Market Status and Outlook (2017-2027)

4.2.3.  UK Market Status and Outlook (2017-2027)

4.2.4.  Russia Market Status and Outlook (2017-2027)

4.2.5.  Italy Market Status and Outlook (2017-2027)

4.2.6.  Rest of Europe Market Status and Outlook (2017-2027)

4.3.     Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)

4.3.1.  China Market Status and Outlook (2017-2027)

4.3.2.  Japan Market Status and Outlook (2017-2027)

4.3.3.  Korea Market Status and Outlook (2017-2027)

4.3.4.  India Market Status and Outlook (2017-2027)

4.3.5.  Southeast Asia Market Status and Outlook (2017-2027)

4.3.6.  Rest of Asia-Pacific Market Status and Outlook (2017-2027)

4.4.     South America (Brazil, Argentina, Columbia and Rest of South America)

4.4.1.  Brazil Market Status and Outlook (2017-2027)

4.4.2.  Argentina Market Status and Outlook (2017-2027)

4.4.3.  Columbia Market Status and Outlook (2017-2027)

4.4.4.  Rest of South America Market Status and Outlook (2017-2027)

4.5.     Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)

4.5.1.  Saudi Arabia Market Status and Outlook (2017-2027)

4.5.2.  United Arab Emirates Market Status and Outlook (2017-2027)

4.5.3.  Egypt Market Status and Outlook (2017-2027)

4.5.4.  Nigeria Market Status and Outlook (2017-2027)

4.5.5.  South Africa Market Status and Outlook (2017-2027)

4.5.6.  Turkey Market Status and Outlook (2017-2027)

4.5.7.  Rest of Middle East and Africa Market Status and Outlook (2017-2027)

5.       Pulmonary Arterial Hypertension Market, By Drug Class

5.1.     Introduction

5.2.     Global Pulmonary Arterial Hypertension Revenue and Market Share by Drug Class (2017-2027)

5.2.1.  Global Pulmonary Arterial Hypertension Revenue and Revenue Share by Drug Class (2017-2027)

5.3.     PDE-5

5.3.1.  Global PDE-5 Revenue and Growth Rate (2017-2027)

5.4.     Prostacyclin and Prostacyclin Analogs

5.4.1.  Global Prostacyclin and Prostacyclin Analogs Revenue and Growth Rate (2017-2027)

5.5.     SGC Stimulators

5.5.1.  Global SGC Stimulators Revenue and Growth Rate (2017-2027)

5.6.     ERA

5.6.1.  Global ERA Revenue and Growth Rate (2017-2027)

6.       Pulmonary Arterial Hypertension Market, By Region

6.1.     Introduction

6.2.     Global Pulmonary Arterial Hypertension Revenue and Market Share by Regions

6.2.1.  Global Pulmonary Arterial Hypertension Revenue by Regions (2017-2027)

6.3.     North America Pulmonary Arterial Hypertension by Countries

6.3.1.  North America Pulmonary Arterial Hypertension Revenue and Growth Rate (2017-2027)

6.3.2.  North America Pulmonary Arterial Hypertension Revenue (Million USD) by Countries (2017-2027)

6.3.3.  United States

6.3.3.1.  United States Pulmonary Arterial Hypertension Revenue (Millions USD) and Growth Rate (2017-2027)

6.3.4.  Canada

6.3.4.1.  Canada Pulmonary Arterial Hypertension Revenue (Millions USD) and Growth Rate (2017-2027)

6.3.5.  Mexico

6.3.5.1.  Mexico Pulmonary Arterial Hypertension Revenue (Millions USD) and Growth Rate (2017-2027)

6.4.     Europe Pulmonary Arterial Hypertension by Countries

6.4.1.  Europe Pulmonary Arterial Hypertension Revenue and Growth Rate (2017-2027)

6.4.2.  Europe Pulmonary Arterial Hypertension Revenue (Million USD) by Countries (2017-2027)

6.4.3.  Germany

6.4.3.1.  Germany Pulmonary Arterial Hypertension Revenue (Millions USD) and Growth Rate (2017-2027)

6.4.4.  France

6.4.4.1.  France Pulmonary Arterial Hypertension Revenue (Millions USD) and Growth Rate (2017-2027)

6.4.5.  UK

6.4.5.1.  UK Pulmonary Arterial Hypertension Revenue (Millions USD) and Growth Rate (2017-2027)

6.4.6.  Russia

6.4.6.1.  Russia Pulmonary Arterial Hypertension Revenue (Millions USD) and Growth Rate (2017-2027)

6.4.7.  Italy

6.4.7.1.  Italy Pulmonary Arterial Hypertension Revenue (Millions USD) and Growth Rate (2017-2027)

6.4.8.  Rest of Europe

6.4.8.1.  Rest of Europe Pulmonary Arterial Hypertension Revenue (Millions USD) and Growth Rate (2017-2027)

6.5.     Asia-Pacific Pulmonary Arterial Hypertension by Countries

6.5.1.  Asia-Pacific Pulmonary Arterial Hypertension Revenue and Growth Rate (2017-2027)

6.5.2.  Asia-Pacific Pulmonary Arterial Hypertension Revenue (Million USD) by Countries (2017-2027)

6.5.3.  China

6.5.3.1.  China Pulmonary Arterial Hypertension Revenue (Millions USD) and Growth Rate (2017-2027)

6.5.4.  Japan

6.5.4.1.  Japan Pulmonary Arterial Hypertension Revenue (Millions USD) and Growth Rate (2017-2027)

6.5.5.  Korea

6.5.5.1.  Korea Pulmonary Arterial Hypertension Revenue (Millions USD) and Growth Rate (2017-2027)

6.5.6.  India

6.5.6.1.  India Pulmonary Arterial Hypertension Revenue (Millions USD) and Growth Rate (2017-2027)

6.5.7.  Southeast Asia

6.5.7.1.  Southeast Asia Pulmonary Arterial Hypertension Revenue (Millions USD) and Growth Rate (2017-2027)

6.5.8.  Rest of Asia-Pacific

6.5.8.1.  Rest of Asia-Pacific Pulmonary Arterial Hypertension Revenue (Millions USD) and Growth Rate (2017-2027)

6.6.     South America Pulmonary Arterial Hypertension by Countries

6.6.1.  South America Pulmonary Arterial Hypertension Revenue and Growth Rate (2017-2027)

6.6.2.  South America Pulmonary Arterial Hypertension Revenue (Million USD) by Countries (2017-2027)

6.6.3.  Brazil

6.6.3.1.  Brazil Pulmonary Arterial Hypertension Revenue (Millions USD) and Growth Rate (2017-2027)

6.6.4.  Argentina

6.6.4.1.  Argentina Pulmonary Arterial Hypertension Revenue (Millions USD) and Growth Rate (2017-2027)

6.6.5.  Columbia

6.6.5.1.  Columbia Pulmonary Arterial Hypertension Revenue (Millions USD) and Growth Rate (2017-2027)

6.6.6.  Rest of South America

6.6.6.1.  Rest of South America Pulmonary Arterial Hypertension Revenue (Millions USD) and Growth Rate (2017-2027)

6.7.     Middle East and Africa Pulmonary Arterial Hypertension by Countries

6.7.1.  Middle East and Africa Pulmonary Arterial Hypertension Revenue and Growth Rate (2017-2027)

6.7.2.  Middle East and Africa Pulmonary Arterial Hypertension Revenue (Million USD) by Countries (2017-2027)

6.7.3.  Saudi Arabia

6.7.3.1.  Saudi Arabia Pulmonary Arterial Hypertension Revenue (Millions USD) and Growth Rate (2017-2027)

6.7.4.  United Arab Emirates

6.7.4.1.  United Arab Emirates Pulmonary Arterial Hypertension Revenue (Millions USD) and Growth Rate (2017-2027)

6.7.5.  Egypt

6.7.5.1.  Egypt Pulmonary Arterial Hypertension Revenue (Millions USD) and Growth Rate (2017-2027)

6.7.6.  Nigeria

6.7.6.1.  Nigeria Pulmonary Arterial Hypertension Revenue (Millions USD) and Growth Rate (2017-2027)

6.7.7.  South Africa

6.7.7.1.  South Africa Pulmonary Arterial Hypertension Revenue (Millions USD) and Growth Rate (2017-2027)

6.7.8.  Turkey

6.7.8.1.  Turkey Pulmonary Arterial Hypertension Revenue (Millions USD) and Growth Rate (2017-2027)

6.7.9.  Rest of Middle East and Africa

6.7.9.1.  Rest of Middle East and Africa Pulmonary Arterial Hypertension Revenue (Millions USD) and Growth Rate (2017-2027)

7.       Company Profiles

7.1.     Gilead Sciences, Inc.

7.1.1.  Business Overview

7.1.2.   Service Portfolio

7.1.3.  Strategic Developments

7.1.4.  Financial Overview

7.2.     United Therapeutics Corporation

7.2.1.  Business Overview

7.2.2.   Service Portfolio

7.2.3.  Strategic Developments

7.2.4.  Financial Overview

7.3.     Novartis International AG

7.3.1.  Business Overview

7.3.2.   Service Portfolio

7.3.3.  Strategic Developments

7.3.4.  Financial Overview

7.4.     Actelion Pharmaceuticals, Ltd

7.4.1.  Business Overview

7.4.2.   Service Portfolio

7.4.3.  Strategic Developments

7.4.4.  Financial Overview

7.5.     Dong-A ST Co., Ltd.

7.5.1.  Business Overview

7.5.2.   Service Portfolio

7.5.3.  Strategic Developments

7.5.4.  Financial Overview

7.6.     Pfizer, Inc.

7.6.1.  Business Overview

7.6.2.   Service Portfolio

7.6.3.  Strategic Developments

7.6.4.  Financial Overview

7.7.     Merck Sharp & Dohme Corp.

7.7.1.  Business Overview

7.7.2.   Service Portfolio

7.7.3.  Strategic Developments

7.7.4.  Financial Overview

7.8.     GlaxoSmithKline Plc. (GSK)

7.8.1.  Business Overview

7.8.2.   Service Portfolio

7.8.3.  Strategic Developments

7.8.4.  Financial Overview

7.9.     Arena Pharmaceuticals

7.9.1.  Business Overview

7.9.2.   Service Portfolio

7.9.3.  Strategic Developments

7.9.4.  Financial Overview

7.10. Bayer HealthCare

7.10.1.      Business Overview

7.10.2.       Service Portfolio

7.10.3.      Strategic Developments

7.10.4.      Financial Overview

8.       Global Pulmonary Arterial Hypertension Market Competition, by Manufacturer

8.1.     Global Pulmonary Arterial Hypertension Financial Overview by Manufacturer (2017-2017)

8.2.     Global Pulmonary Arterial Hypertension Price By Region (2017-2017)

8.3.     Top 5 Pulmonary Arterial Hypertension Manufacturer Market Share

8.4.     Market Competition Trend

9.       Pulmonary Arterial Hypertension Market Forecast (2017-2027)

9.1.     Global Pulmonary Arterial Hypertension Revenue (Millions USD) and Growth Rate (2017-2027)

9.2.     Pulmonary Arterial Hypertension Market Forecast by Regions (2017-2027)

9.2.1.  North America Pulmonary Arterial Hypertension Market Forecast (2017-2027)

9.2.1.1.  United States Pulmonary Arterial Hypertension Market Forecast (2017-2027)

9.2.1.2.  Canada Pulmonary Arterial Hypertension Market Forecast (2017-2027)

9.2.1.3.  Mexico Pulmonary Arterial Hypertension Market Forecast (2017-2027)

9.2.2.  Europe Pulmonary Arterial Hypertension Market Forecast (2017-2027)

9.2.2.1.  Germany Pulmonary Arterial Hypertension Market Forecast (2017-2027)

9.2.2.2.  France Pulmonary Arterial Hypertension Market Forecast (2017-2027)

9.2.2.3.  UK Pulmonary Arterial Hypertension Market Forecast (2017-2027)

9.2.2.4.  Russia Pulmonary Arterial Hypertension Market Forecast (2017-2027)

9.2.2.5.  Italy Pulmonary Arterial Hypertension Market Forecast (2017-2027)

9.2.2.6.  Rest of Europe Pulmonary Arterial Hypertension Market Forecast (2017-2027)

9.2.3.  Asia-Pacific Pulmonary Arterial Hypertension Market Forecast (2017-2027)

9.2.3.1.  China Pulmonary Arterial Hypertension Market Forecast (2017-2027)

9.2.3.2.  Japan Pulmonary Arterial Hypertension Market Forecast (2017-2027)

9.2.3.3.  Korea Pulmonary Arterial Hypertension Market Forecast (2017-2027)

9.2.3.4.  India Pulmonary Arterial Hypertension Market Forecast (2017-2027)

9.2.3.5.  Southeast Asia Pulmonary Arterial Hypertension Market Forecast (2017-2027)

9.2.3.6.  Rest of Asia-Pacific Pulmonary Arterial Hypertension Market Forecast (2017-2027)

9.2.4.  South America Pulmonary Arterial Hypertension Market Forecast (2017-2027)

9.2.4.1.  Brazil Pulmonary Arterial Hypertension Market Forecast (2017-2027)

9.2.4.2.  Argentina Pulmonary Arterial Hypertension Market Forecast (2017-2027)

9.2.4.3.  Columbia Pulmonary Arterial Hypertension Market Forecast (2017-2027)

9.2.4.4.  Rest of South America Pulmonary Arterial Hypertension Market Forecast (2017-2027)

9.2.5.  Middle East and Africa Pulmonary Arterial Hypertension Market Forecast (2017-2027)

9.2.5.1.  Saudi Arabia Pulmonary Arterial Hypertension Market Forecast (2017-2027)

9.2.5.2.  United Arab Emirates Pulmonary Arterial Hypertension Market Forecast (2017-2027)

9.2.5.3.  Egypt Pulmonary Arterial Hypertension Market Forecast (2017-2027)

9.2.5.4.  Nigeria Pulmonary Arterial Hypertension Market Forecast (2017-2027)

9.2.5.5.  South Africa Pulmonary Arterial Hypertension Market Forecast (2017-2027)

9.2.5.6.  Turkey Pulmonary Arterial Hypertension Market Forecast (2017-2027)

9.2.5.7.  Rest of Middle East and Africa Pulmonary Arterial Hypertension Market Forecast (2017-2027)

9.3.     Pulmonary Arterial Hypertension Market Forecast by Drug Class (2017-2027)

9.3.1.  Pulmonary Arterial Hypertension Forecast by Drug Class (2017-2027)

9.3.2.  Pulmonary Arterial Hypertension Market Share Forecast by Drug Class (2017-2027)

List of Tables

List of Tables and Figures:

Figure United States Pulmonary Arterial Hypertension Revenue (Million USD) and Growth Rate (2017-2025)
Figure Canada Pulmonary Arterial Hypertension Revenue (Million USD) and Growth Rate (2017-2025)
Figure Mexico Pulmonary Arterial Hypertension Revenue (Million USD) and Growth Rate (2017-2025)
Figure Germany Pulmonary Arterial Hypertension Revenue (Million USD) and Growth Rate (2017-2025)
Figure France Pulmonary Arterial Hypertension Revenue (Million USD) and Growth Rate (2017-2025)
Figure UK Pulmonary Arterial Hypertension Revenue (Million USD) and Growth Rate (2017-2025)
Figure Russia Pulmonary Arterial Hypertension Revenue (Million USD) and Growth Rate (2017-2025)
Figure Italy Pulmonary Arterial Hypertension Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Europe Pulmonary Arterial Hypertension Revenue (Million USD) and Growth Rate (2017-2025)
Figure China Pulmonary Arterial Hypertension Revenue (Million USD) and Growth Rate (2017-2025)
Figure Japan Pulmonary Arterial Hypertension Revenue (Million USD) and Growth Rate (2017-2025)
Figure Korea Pulmonary Arterial Hypertension Revenue (Million USD) and Growth Rate (2017-2025)
Figure India Pulmonary Arterial Hypertension Revenue (Million USD) and Growth Rate (2017-2025)
Figure Southeast Asia Pulmonary Arterial Hypertension Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Asia-Pacific Pulmonary Arterial Hypertension Revenue (Million USD) and Growth Rate (2017-2025)
Figure Brazil Pulmonary Arterial Hypertension Revenue (Million USD) and Growth Rate (2017-2025)
Figure Argentina Pulmonary Arterial Hypertension Revenue (Million USD) and Growth Rate (2017-2025)
Figure Columbia Pulmonary Arterial Hypertension Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of South America Pulmonary Arterial Hypertension Revenue (Million USD) and Growth Rate (2017-2025)
Figure Saudi Arabia Pulmonary Arterial Hypertension Revenue (Million USD) and Growth Rate (2017-2025)
Figure United Arab Emirates Pulmonary Arterial Hypertension Revenue (Million USD) and Growth Rate (2017-2025)
Figure Egypt Pulmonary Arterial Hypertension Revenue (Million USD) and Growth Rate (2017-2025)
Figure Nigeria Pulmonary Arterial Hypertension Revenue (Million USD) and Growth Rate (2017-2025)
Figure South Africa Pulmonary Arterial Hypertension Revenue (Million USD) and Growth Rate (2017-2025)
Figure Turkey Pulmonary Arterial Hypertension Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Middle East and Africa Pulmonary Arterial Hypertension Revenue (Million USD) and Growth Rate (2017-2025)
Table Global Pulmonary Arterial Hypertension Revenue and Revenue Share by Drug Class (2017-2018)
Figure Global PDE-5 Revenue and Growth Rate (2017-2018)
Figure Global Prostacyclin and Prostacyclin Analogs Revenue and Growth Rate (2017-2018)
Figure Global SGC Stimulators Revenue and Growth Rate (2017-2018)
Figure Global ERA Revenue and Growth Rate (2017-2018)
Table Global Pulmonary Arterial Hypertension Revenue by Regions (2017-2018)
Figure North America Pulmonary Arterial Hypertension Growth Rate (2017-2018)
Figure North America Pulmonary Arterial Hypertension Revenue and Growth Rate (2017-2018)
Figure North America Pulmonary Arterial Hypertension by Countries (2017-2018)
Figure North America Pulmonary Arterial Hypertension Revenue (Million USD) by Countries (2017-2018)
Figure United States Pulmonary Arterial Hypertension Growth Rate (2017-2018)
Figure United States Pulmonary Arterial Hypertension Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Canada Pulmonary Arterial Hypertension Growth Rate (2017-2018)
Figure Canada Pulmonary Arterial Hypertension Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Mexico Pulmonary Arterial Hypertension Growth Rate (2017-2018)
Figure Mexico Pulmonary Arterial Hypertension Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Europe Pulmonary Arterial Hypertension Growth Rate (2017-2018)
Figure Europe Pulmonary Arterial Hypertension Revenue and Growth Rate (2017-2018)
Figure Europe Pulmonary Arterial Hypertension by Countries (2017-2018)
Figure Europe Pulmonary Arterial Hypertension Revenue (Million USD) by Countries (2017-2018)
Figure Germany Pulmonary Arterial Hypertension Growth Rate (2017-2018)
Figure Germany Pulmonary Arterial Hypertension Revenue (Millions USD) and Growth Rate (2017-2018)
Figure France Pulmonary Arterial Hypertension Growth Rate (2017-2018)
Figure France Pulmonary Arterial Hypertension Revenue (Millions USD) and Growth Rate (2017-2018)
Figure UK Pulmonary Arterial Hypertension Growth Rate (2017-2018)
Figure UK Pulmonary Arterial Hypertension Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Russia Pulmonary Arterial Hypertension Growth Rate (2017-2018)
Figure Russia Pulmonary Arterial Hypertension Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Italy Pulmonary Arterial Hypertension Growth Rate (2017-2018)
Figure Italy Pulmonary Arterial Hypertension Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Europe Pulmonary Arterial Hypertension Growth Rate (2017-2018)
Figure Rest of Europe Pulmonary Arterial Hypertension Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Asia-Pacific Pulmonary Arterial Hypertension Growth Rate (2017-2018)
Figure Asia-Pacific Pulmonary Arterial Hypertension Revenue and Growth Rate (2017-2018)
Figure Asia-Pacific Pulmonary Arterial Hypertension by Countries (2017-2018)
Figure Asia-Pacific Pulmonary Arterial Hypertension Revenue (Million USD) by Countries (2017-2018)
Figure China Pulmonary Arterial Hypertension Growth Rate (2017-2018)
Figure China Pulmonary Arterial Hypertension Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Japan Pulmonary Arterial Hypertension Growth Rate (2017-2018)
Figure Japan Pulmonary Arterial Hypertension Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Korea Pulmonary Arterial Hypertension Growth Rate (2017-2018)
Figure Korea Pulmonary Arterial Hypertension Revenue (Millions USD) and Growth Rate (2017-2018)
Figure India Pulmonary Arterial Hypertension Growth Rate (2017-2018)
Figure India Pulmonary Arterial Hypertension Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Southeast Asia Pulmonary Arterial Hypertension Growth Rate (2017-2018)
Figure Southeast Asia Pulmonary Arterial Hypertension Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Pulmonary Arterial Hypertension Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Pulmonary Arterial Hypertension Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South America Pulmonary Arterial Hypertension Growth Rate (2017-2018)
Figure South America Pulmonary Arterial Hypertension Revenue and Growth Rate (2017-2018)
Figure South America Pulmonary Arterial Hypertension by Countries (2017-2018)
Figure South America Pulmonary Arterial Hypertension Revenue (Million USD) by Countries (2017-2018)
Figure Brazil Pulmonary Arterial Hypertension Growth Rate (2017-2018)
Figure Brazil Pulmonary Arterial Hypertension Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Argentina Pulmonary Arterial Hypertension Growth Rate (2017-2018)
Figure Argentina Pulmonary Arterial Hypertension Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Columbia Pulmonary Arterial Hypertension Growth Rate (2017-2018)
Figure Columbia Pulmonary Arterial Hypertension Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of South America Pulmonary Arterial Hypertension Growth Rate (2017-2018)
Figure Rest of South America Pulmonary Arterial Hypertension Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Middle East and Africa Pulmonary Arterial Hypertension Growth Rate (2017-2018)
Figure Middle East and Africa Pulmonary Arterial Hypertension Revenue and Growth Rate (2017-2018)
Figure Middle East and Africa Pulmonary Arterial Hypertension by Countries (2017-2018)
Figure Middle East and Africa Pulmonary Arterial Hypertension Revenue (Million USD) by Countries (2017-2018)
Figure Saudi Arabia Pulmonary Arterial Hypertension Growth Rate (2017-2018)
Figure Saudi Arabia Pulmonary Arterial Hypertension Revenue (Millions USD) and Growth Rate (2017-2018)
Figure United Arab Emirates Pulmonary Arterial Hypertension Growth Rate (2017-2018)
Figure United Arab Emirates Pulmonary Arterial Hypertension Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Egypt Pulmonary Arterial Hypertension Growth Rate (2017-2018)
Figure Egypt Pulmonary Arterial Hypertension Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Nigeria Pulmonary Arterial Hypertension Growth Rate (2017-2018)
Figure Nigeria Pulmonary Arterial Hypertension Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South Africa Pulmonary Arterial Hypertension Growth Rate (2017-2018)
Figure South Africa Pulmonary Arterial Hypertension Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Turkey Pulmonary Arterial Hypertension Growth Rate (2017-2018)
Figure Turkey Pulmonary Arterial Hypertension Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Pulmonary Arterial Hypertension Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Pulmonary Arterial Hypertension Revenue (Millions USD) and Growth Rate (2017-2018)
Table Gilead Sciences, Inc. Pulmonary Arterial Hypertension Price, Revenue, Gross Margin and Market Share (2017-2017)
Table United Therapeutics Corporation Pulmonary Arterial Hypertension Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Novartis International AG Pulmonary Arterial Hypertension Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Actelion Pharmaceuticals, Ltd Pulmonary Arterial Hypertension Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Dong-A ST Co., Ltd. Pulmonary Arterial Hypertension Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Pfizer, Inc. Pulmonary Arterial Hypertension Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Merck Sharp & Dohme Corp. Pulmonary Arterial Hypertension Price, Revenue, Gross Margin and Market Share (2017-2017)
Table GlaxoSmithKline Plc. (GSK) Pulmonary Arterial Hypertension Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Arena Pharmaceuticals Pulmonary Arterial Hypertension Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Bayer HealthCare Pulmonary Arterial Hypertension Price, Revenue, Gross Margin and Market Share (2017-2017)
Figure Global Pulmonary Arterial Hypertension Market Share by Manufacturer
Figure Global Pulmonary Arterial Hypertension Revenue and Market Share by Manufacturer
Table Global Pulmonary Arterial Hypertension Price by Region (2017-2017)
Figure Top 5 Pulmonary Arterial Hypertension Manufacturer (Revenue) Market Share
Figure Market Competition Trend
Figure Global Pulmonary Arterial Hypertension Revenue (Millions USD) and Growth Rate (2018-2025)
Table Pulmonary Arterial Hypertension Market Forecast by Regions (2018-2025)
Figure North America Pulmonary Arterial Hypertension Market Forecast (2018-2025)
Figure United States Pulmonary Arterial Hypertension Market Forecast (2018-2025)
Figure Canada Pulmonary Arterial Hypertension Market Forecast (2018-2025)
Figure Mexico Pulmonary Arterial Hypertension Market Forecast (2018-2025)
Figure Europe Pulmonary Arterial Hypertension Market Forecast (2018-2025)
Figure Germany Pulmonary Arterial Hypertension Market Forecast (2018-2025)
Figure France Pulmonary Arterial Hypertension Market Forecast (2018-2025)
Figure UK Pulmonary Arterial Hypertension Market Forecast (2018-2025)
Figure Russia Pulmonary Arterial Hypertension Market Forecast (2018-2025)
Figure Italy Pulmonary Arterial Hypertension Market Forecast (2018-2025)
Figure Rest of Europe Pulmonary Arterial Hypertension Market Forecast (2018-2025)
Figure Asia-Pacific Pulmonary Arterial Hypertension Market Forecast (2018-2025)
Figure China Pulmonary Arterial Hypertension Market Forecast (2018-2025)
Figure Japan Pulmonary Arterial Hypertension Market Forecast (2018-2025)
Figure Korea Pulmonary Arterial Hypertension Market Forecast (2018-2025)
Figure India Pulmonary Arterial Hypertension Market Forecast (2018-2025)
Figure Southeast Asia Pulmonary Arterial Hypertension Market Forecast (2018-2025)
Figure Rest of Asia-Pacific Pulmonary Arterial Hypertension Market Forecast (2018-2025)
Figure South America Pulmonary Arterial Hypertension Market Forecast (2018-2025)
Figure Brazil Pulmonary Arterial Hypertension Market Forecast (2018-2025)
Figure Argentina Pulmonary Arterial Hypertension Market Forecast (2018-2025)
Figure Columbia Pulmonary Arterial Hypertension Market Forecast (2018-2025)
Figure Rest of South America Pulmonary Arterial Hypertension Market Forecast (2018-2025)
Figure Middle East and Africa Pulmonary Arterial Hypertension Market Forecast (2018-2025)
Figure Saudi Arabia Pulmonary Arterial Hypertension Market Forecast (2018-2025)
Figure United Arab Emirates Pulmonary Arterial Hypertension Market Forecast (2018-2025)
Figure Egypt Pulmonary Arterial Hypertension Market Forecast (2018-2025)
Figure Nigeria Pulmonary Arterial Hypertension Market Forecast (2018-2025)
Figure South Africa Pulmonary Arterial Hypertension Market Forecast (2018-2025)
Figure Turkey Pulmonary Arterial Hypertension Market Forecast (2018-2025)
Figure Rest of Middle East and Africa Pulmonary Arterial Hypertension Market Forecast (2018-2025)
Figure Global Pulmonary Arterial Hypertension Forecast by Drug Class (2018-2025)
Figure Global Pulmonary Arterial Hypertension Market Share Forecast by Drug Class (2018-2025)
Figure Global Pulmonary Arterial Hypertension Forecast by Drug Class (2018-2025)

Please Note: Data related to the Companies are subject to Availability.

Research Methodology

We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.

Data Mining

Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.

Data Collection Matrix

Data Collection Matrix

Supply Side

Demand Side

Primary Data Sources
  • Manufacturers
  • Distributors & Wholesalers
  • GPOs
  • Physicians/Specialist
  • Healthcare Providers
  • Consumers

Secondary Data Sources
  • Annual Reports/SEC Filings/ Investor Presentations/ Press Releases
  • Government/Associations Publications
  • Case Studies
  • Reference Customers

 

Market Modeling and Forecasting

We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.

  • Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
  • Number of patients for particular device or medical procedure and
  • Repeated use of particular device depending on health and condition of patient
  • Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.

We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.

Data Validation

We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.

Data Triangulation

data triangulation

Industry Analysis

Qualitative Data

Quantitative Data (2017-2025)
  • Market Dynamics (Drivers, Restraints, and Challenges)
  • Industry Trend Analysis
  • Market Opportunities
  • Government Policies and Regulations, Patent Analysis, and Reimbursement Policies
  • Porter’s Five Forces and PESTLE Analysis
  • Key Developments and Competitive Landscape
  • Market Assessment and Forecast
  • Market Assessment and Forecast, By Product
  • Market Assessment and Forecast, By Technology
  • Market Assessment and Forecast, By Application
  • Market Assessment and Forecast, By End User
  • Market Assessment and Forecast, By Region/Country

License Type

For Any Assistance

*
*
*
*
*